Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

Phase 1 Completed 14 enrolled Baylor College of Medicine National Cancer Institute (NCI) · collab

Parallel-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of a peptide vaccine in treating patients with metastatic prostate cancer.

Timeline

Start: 2006-04
Primary completion: 2011-07
Completion: 2011-07

Publications

Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann MM, Wheeler TM, Gee AP, Wang RF, Hayes TG. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr;32(2):235-242. doi: 10.1007/s10637-013-9960-9. Epub 2013 Apr 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine	Peptide	1000 ug	Subcutaneous

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications